Benzyl isothiocyanate inhibits HNSCC cell migration and invasion, and sensitizes hnscc cells to cisplatin

Nutrition and Cancer

Volumn 66, Issue 2, 2014, Pages 285-294

  Wolf, M Allison ^a   Claudio, Pier Paolo ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL ISOTHIOCYANATE; CISPLATIN; VIMENTIN;

ARTICLE; CELL COUNT; CELL DEATH; CELL INVASION; CELL LINE; CELL MIGRATION; CELL STRAIN HN12; CELL STRAIN HN30; CELL STRAIN HN8; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; METASTASIS; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; ISOTHIOCYANATES; VIMENTIN;

EID: 84895132352     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.868912     Document Type: Article

References (35)

1. Sayed SI, Dwivedi RC, Katna R, Garg A, Pathak KA, et al.: Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol 47, 237-243, 2011.
2. de Andrade DA, and Machiels JP: Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. Current Opinion in Oncology 24, 211-217, 2012.
3. Kurzweg T, Mockelmann N, Laban S, and Knecht R: Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies 269, 2157-2167, 2012.
4. Price KA, and Cohen EE: Current treatment options for metastatic head and neck cancer. Current Treatment Options in Oncology 13, 35-46, 2012.
5. Lee DH, Kim MJ, Roh JL, Kim SB, Choi SH, et al.: Distant metastases and survival prediction in head and neck squamous cell carcinoma. Otolaryngology-Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery 147, 870-875, 2012.
6. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, et al.: Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and Power Blot. Clin Cancer Res 8, 3910-3921, 2002. (Pubitemid 35424786)
7. Chen ZG: The cancer stem cell concept in progression of head and neck cancer. J Oncol 2009, 894064, 2009.
8. Bourguignon LY, Earle C, Wong G, Spevak CC, and Krueger K: Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 31, 149-160, 2012.
9. Nakamura Y: Chemoprevention by isothiocyanates: molecular basis of apoptosis induction. Forum Nutr 61, 170-181, 2009.
10. Nakamura Y and Miyoshi N: Electrophiles in foods: the current status of isothiocyanates and their chemical biology. Biosci Biotechnol Biochem 74, 242-255, 2010.
11. Wu X, Zhou QH, and Xu K: Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin 30, 501-512, 2009.
12. Cheung KL, and Kong AN: Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. Aaps J 12, 87-97, 2009.
13. Mi L, Hood BL, Stewart NA, Xiao Z, Govind S, et al.: Identification of potential protein targets of isothiocyanates by proteomics. Chem Res Toxicol 24, 1735-1743, 2011.
14. Mi L, Xiao Z, Veenstra TD, and Chung FL: Proteomic identification of binding targets of isothiocyanates: A perspective on techniques. J Proteomics 74, 1036-1044, 2011.
15. Hutzen B, Willis W, Jones S, Cen L, Deangelis S, et al.: Dietary agent, benzyl isothiocyanate inhibits signal transducer and activator of transcription 3 phosphorylation and collaborates with sulforaphane in the growth suppression of PANC-1 cancer cells. Cancer Cell Int 9, 24, 2009.
16. Zhang R, Loganathan S, Humphreys I, and Srivastava SK: Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. J Nutr 136, 2728-2734, 2006. (Pubitemid 44771765)
17. Boreddy SR, Sahu RP, and Srivastava SK: Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIFalpha/VEGF/Rho- GTPases: pivotal role of STAT-3. PLoS One 6, e25799, 2011.
18. Warin R, Chambers WH, Potter DM, and Singh SV: Prevention ofmammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate. Cancer Res 69, 9473-9480, 2009.
19. Warin R, Xiao D, Arlotti JA, Bommareddy A, and Singh SV: Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate. Mol Carcinog 49, 500-507, 2010.
20. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, et al.: Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65, 9953-9961, 2005. (Pubitemid 41541476)
21. Zhao L, Au JL-S, and Wientjes MG: Comparison of methods for evaluating drug-drug interaction. Frontieer Bioscience 2, 241-249, 2010.
22. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, et al.: Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112, 2088-2100, 2008. (Pubitemid 351574086)
23. Nijkamp MM, Span PN, Hoogsteen IJ, van der Kogel AJ, Kaanders JH, et al.: Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol 99, 344-348, 2011.
24. Judson I, and Kelland LR: New developments and approaches in the platinum arena. Drugs 59(Suppl 4), 29-36; discussion 7-8, 2000. (Pubitemid 30344989)
25. Giaccone G: Clinical perspectives on platinum resistance. Drugs 59(Suppl 4), 9-17; discussion 37-38, 2000. (Pubitemid 30344987)
26. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279, 2003. (Pubitemid 37487159)
27. Mishima M, Samimi G, Kondo A, Lin X, and Howell SB: The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38, 1405-1412, 2002. (Pubitemid 34686853)
28. Keski-Santti H, Atula T, Tikka J, Hollmen J, Makitie AA, et al.: Predictive value of histopathologic parameters in early squamous cell carcinoma of oral tongue. Oral Oncol 43, 1007-1013, 2007. (Pubitemid 47532776)
29. Chung FL, Jiao D, Getahun SM, and Yu MC:Aurinary biomarker for uptake of dietary isothiocyanates in humans. Cancer Epidemiol Biomarkers Prev 7, 103-108, 1998. (Pubitemid 28109840)
30. Sehrawat A, and Singh SV: Benzyl isothiocyanate inhibits epithelialmesenchymal transition in cultured and xenografted human breast cancer cells. Cancer Prev Res (Phila) 4, 1107-1117, 2011.
31. Steck SE, Gammon MD, Hebert JR, Wall DE, and Zeisel SH: GSTM1, GSTT1, GSTP1, and GSTA1 polymorphisms and urinary isothiocyanate metabolites following broccoli consumption in humans. J Nutr 137, 904-909, 2007. (Pubitemid 46596885)
32. Lamy E, Scholtes C, Herz C, and Mersch-Sundermann V: Pharmacokinetics and pharmacodynamics of isothiocyanates. Drug Metab Rev 43, 387-407, 2011.
33. Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and molecular life sciences: CMLS 68, 3033-3046, 2011.
34. Delord JP, Puozzo C, Lefresne F, and Bugat R: Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors. Anticancer Research 29, 553-560, 2009.
35. Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, et al.: Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin Cancer Res 14, 7947-7955, 2008.